Commonwealth Equity Services LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 1.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 17,920 shares of the medical research company’s stock after selling 264 shares during the quarter. Commonwealth Equity Services LLC’s holdings in IQVIA were worth $3,564,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of IQV. HighTower Advisors LLC grew its position in shares of IQVIA by 2.4% in the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after purchasing an additional 118 shares during the period. Prudential PLC acquired a new position in IQVIA during the 1st quarter worth approximately $741,000. Baird Financial Group Inc. boosted its position in IQVIA by 2.3% during the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after acquiring an additional 2,201 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in IQVIA by 59.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock worth $90,000 after acquiring an additional 144 shares during the last quarter. Finally, Covestor Ltd boosted its position in IQVIA by 82.2% during the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock worth $128,000 after acquiring an additional 250 shares during the last quarter. 86.82% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Stock Up 0.8 %
IQV opened at $224.33 on Monday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 2.16. The stock has a market cap of $41.08 billion, a PE ratio of 38.61, a price-to-earnings-growth ratio of 2.27 and a beta of 1.37. The stock’s fifty day simple moving average is $220.55 and its 200 day simple moving average is $207.86. IQVIA Holdings Inc. has a 1-year low of $165.75 and a 1-year high of $241.86.
Wall Street Analyst Weigh In
IQV has been the subject of a number of recent research reports. Barclays upped their price target on IQVIA from $230.00 to $250.00 in a research report on Tuesday, June 27th. StockNews.com began coverage on IQVIA in a research report on Thursday, August 17th. They set a “hold” rating for the company. Citigroup upped their price objective on IQVIA from $200.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus upped their price objective on IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Finally, Truist Financial upped their price objective on IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $251.38.
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Five stocks we like better than IQVIA
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 8/28 – 9/1
- How to Invest in Casino Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Use Stock Screeners to Find Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.